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Abstract
Family history of breast and related cancers can indicate increased breast cancer (BC) risk. In national familial breast cancer
(FBC) guidelines, the risk is stratified to guide referral decisions. We aimed to identify characteristics associated with the
recommendation for referral in a large cohort of women undergoing FBC risk assessment in a recent primary care study.
Demographic, family history, psychological and behavioural factors were collected with family history questionnaires, psycho-
logical questionnaires and manual data extraction from general practice electronic health records. Participants were women aged
30–60 with no previous history of breast or ovarian cancer. Data from 1127 women were analysed with stepwise logistic
regression. Two multivariable logistic models were developed to predict recommendations for referral: using the entire cohort
(n = 1127) and in a subgroup with uncertain risks (n = 168). Model performance was assessed by the area under the receiver
operating curve (AUC). In all 1127 women, a multivariable model incorporating five family history components (BC aged < 40,
bilateral BC, prostate cancer, first degree relative with ovarian cancer, paternal family history of BC) and having a mammogram
in the last 3 years, performed well (AUC = 0.86). For the 168 uncertain risk women, only paternal family history of BC remained
significant (AUC = 0.71). Clinicians should pay particular attention to these five family history components when assessing FBC
risk, especially prostate cancer which is not in the current national guidelines.
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Introduction
Breast cancer is the most common cancer in women (World
Cancer Research Fund 2018). In developed countries, one in
eight women will develop breast cancer in their lifetime
(American Cancer Society 2019; Cancer Research UK
2018a, b). Family histories of breast and related cancers are
recognised risk factors and have been used to stratify disease
risk. Around 5–10% of breast cancers are caused by an
inherited faulty genes such as the BRCA1 and BRCA2 genes
(Cancer Research UK 2014; Cancer Research UK 2018a, b).
For patients at familial risk of breast cancer preventive
measures such as risk-reducing prophylactic surgery, chemo-
prevention or increased surveillance can reduce cancer inci-
dence and/or mortality (Carbine et al. 2018; Cuzick et al.
2013; Domchek et al. 2010; Duffy et al. 2013). In England,
the National Institute for Health and Care Excellence (NICE)
guideline for identification and management of familial breast
cancer risk includes referral criteria for general practitioners
(NICE 2013). Familial breast cancer risk assessment enables
primary care clinicians to identify patients who meet the
criteria for specialist referral to access further assessment
and management, which may include genetic counselling, ge-
netic testing and preventive measures.
The NICE guideline, as well as classifying women into
high and moderate risk with clear management plans, clas-
sifies a significant minority of women with uncertain risk.
Rather than a direct referral, NICE recommends seeking ad-
vice from secondary care specialists on the management/
referral of these women (NICE 2013). The challenge of famil-
ial breast cancer risk assessment in primary care is further
compounded by the lack of detailed cancer family history
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recording in primary care records (Murff et al. 2004; Tyler and
Snyder 2006).
In a recent study that evaluated a systematic approach to
identify women at risk of familial breast cancer in primary
care, using postal family history questionnaires sent to women
aged 30 to 60, one in seven women was assessed as having
uncertain risk (NIHR SPCR 2013; Chorley et al. 2016).
Obtaining specialist opinion for these patients would be a
significant workload for both general practitioners and spe-
cialists. It also delays patients from receiving appropriate re-
assurance or specialist care which may cause anxiety and re-
sult in presentation in primary care and subsequent possible
inappropriate referral to secondary care.
In this study, we explored the demographic, family history,
psychological and behavioural factors that are associated with
the recommendation for specialist referral for familial breast
cancer, with the aim to improve primary care decision-making
when managing women with family history of breast and
related cancers.
Materials and methods
This is an observational cohort study with demographic, fam-
ily history, psychological and behavioural factors collected
from patients using a validated family history questionnaire,
psychological questionnaires and manual data extraction from
general practice electronic health records (NIHR SPCR 2013;
Qureshi et al. 2005). We used the patient cohort from a recent
study on familial breast cancer risk assessment in primary
care: eight general practices in East Midlands were recruited;
recruits were women aged 30–60 with no previous personal
history of breast or ovarian cancer (NIHR SPCR 2013).
Familial breast cancer risk was assessed based on family his-
tory, against the NICE guideline recommendations, using a
validated family history questionnaire, the FAHRAS decision
support software and specialist advice (for those with uncer-
tain risk) (Gorman et al. 2014). For this secondary analysis,
we used the data for 1127 participants recruited systematically
and undergoing full risk assessment between dates June 2014
and January 2015.
The dependent variable was the final recommended clinical
pathway for the participants following the risk assessment:
refer to secondary care (event) or manage in primary care
(no event). Box 1 lists the independent variables. The family
history data were recoded into variables according to the
NICE familial breast cancer referral criteria, such as bilateral
breast cancer, male breast cancer, paternal family history of
breast cancer, number of first- or second-degree relatives af-
fected and age of diagnosis (NICE 2013). Participant’s occu-
pation was recoded using the UKOffice for National Statistics
occupation classification using the Cascot software, a
computer-assisted structured coding tool (Office for National
Statistics 2010; Warwick Institute for Employment Research
2018).
For continuous data, we conducted median imputation for
missing data; for categorical data, missing data were recoded
as a separate category of ‘not reported’.
Box 1 Independent variables
Demographics
• Age (years)






• Total number of FDR (continuous)
• Total number of SDR (continuous)
• Number of FDR with breast or ovarian cancer (0 vs = > 1, categorical)
• Number of FDR with breast cancer (0 vs = > 1, categorical)
• Number of FDR with ovarian cancer (0 vs 1, categorical)
• Number of SDR with breast or ovarian cancer (0 vs = > 1, categorical)
• Number of paternal relatives with breast cancer (0 vs = > 1, categorical)
• Number of paternal relatives with ovarian cancer
(0 vs = > 1, categorical)
• Number of paternal relatives with breast and ovarian cancer
(0 vs 1, categorical)
• Number of relatives with breast or ovarian cancer
(0 vs = > 1, categorical)
• Number of relatives with breast and ovarian cancer (0 vs 1, categorical)
• Number of relatives with bilateral breast cancer (0 vs = > 1, categorical)
• Number of male relatives with breast cancer (0 vs 1, categorical)
• Number of relatives with breast cancer diagnosed under age 40
(0 vs = > 1, categorical)
• Number of FDR with breast cancer diagnosed under age 40
(0 vs 1, categorical)
• Number of SDR with breast cancer diagnosed under age 40
(0 vs = > 1, categorical)
• Number of relatives with prostate cancer (0 vs = > 1, categorical)
• Number of paternal relatives with prostate cancer
(0 vs = > 1, categorical)
• Number of maternal relatives with prostate cancer
(0 vs = > 1, categorical)
• Number of FDR with prostate cancer (0 vs = > 1, categorical)
• Number of relatives with colorectal cancer (0 vs = > 1, categorical)
• Number of paternal relatives with colorectal cancer
(0 vs = > 1, categorical)
• Number of maternal relatives with colorectal cancer
(0 vs = > 1, categorical)
• Number of FDR with colorectal cancer (0 vs 1, categorical)
• Number of relatives with any cancer (continuous)
•Number of relatives with sarcoma/adrenal/brain cancer
(0 vs = > 1, categorical)
• Number of relatives with non-breast cancer diagnosed under age 40
(0 vs 1, categorical)
• Number of relatives that died of cancer (0 vs = > 1, categorical)
• Number of relatives that died of cancer aged < 40 (0 vs 1, categorical)
• Ratio of FDR with breast cancer to total FDR (continuous)
• Ratio of FDR with breast/ovarian cancer to total FDR (continuous)
• Ratio of SDR with breast/ovarian cancer to total SDR (continuous)
Psychological factors (baseline patient questionnaire)
• Lerman Breast Cancer Worry (categorical),
Cancer Worry Impact Index (continuous)
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Statistical analysis
STATA version 13.1 was used for the statistical analysis.
p < 0.05 was considered significant. Bonferroni correction
was used for psychological measures with multiple items to
account for correlation between measures.
Demographics for non-participating women were obtained
by electronic search from anonymised primary care health
records. Age (median) and ethnicity (white and non-white)
were compared between participating and non-participating
women using two-sample Wilcoxon rank-sum test and
Pearson Chi-square test respectively.
Univariate analysis was performed using logistic regression
for continuous and binary categorical variables. For non-binary
categorical variables, likelihood ratio test was performed
against a base model that included age and Index of Multiple
Deprivation (IMD) as a priori demographic variables.
Significant variables were then included in the multivariable
analysis, with age and IMD quintiles considered a priori.
Variables were then removed in stepwise backward elimination
to give the final model predicting a recommendation of referral
to secondary care. The final model was then applied to the
subgroup of participants who were in the uncertain risk group.
The area under the receiver operating curve (AUC) was gener-
ated to test model performance, a measure of discriminatory
accuracy of the model to distinguish between outcome events.
Results
Demographics of the study population
From the initial electronic records search, 10,080womenwere
potentially eligible based on the inclusion criteria. After
further review of eligibility by general practitioners, 7012
women were invited to participate; 1127 (16%) consented
and completed the familial breast cancer risk assessment in
primary care. Reasons for exclusion by general practitioners
were unknown due to data protection and privacy laws.
Ethnicity and age data for the 8953 potentially eligible women
who did not join the study were extracted from the primary
care records. These non-participants included both those that
were not invited to participate (3068) and those who declined
invitation to participate (5885). It was not possible to distin-
guish from the anonymised non-participant data those who
were not invited.
The median time from participants returning the family
history questionnaire (risk assessment) to participants receiv-
ing an outcome letter (refer or manage in primary care) was
27 days (interquartile range 15 to 43 days). The demographics
for the 1127 participants are presented in Table 1. There was a
relatively equal spread across all types of education and occu-
pation. Most participants were in the less deprived IMD quin-
tiles (50% in the 4th and 5th quintiles). As the number of non-
white participants was very small (2%), they were combined
into a single category. There was one of European Jewish
ancestry, and three of mixed ethnicity with Jewish ancestry;
only one was recommended referral.
For the 8953 non-participating women, the median age was
46 years (interquartile range 39–52); 37% (3271/8953) had no
ethnicity recorded in their primary care records. Despite this
being a known problem with routinely collected primary care
data sources, primary care ethnicity data are generally compa-
rable with the UK census (Mathur et al. 2014).White ethnicity
comprised 97% (5509/5682) of non-participating womenwith
recorded ethnicity, similar to the ethnicity profile for the bor-
ough of the participating general practices (96%) (Office for
National Statistics 2012). Comparing the 1127 participants
with the non-participants, although there was a significant
difference for age (p = 0.003), both groups had a median age
of 46 years. For those with reported ethnicity, participation
rate was 17% (1099/6608) for white participants and 11%
(22/195) for non-white participants; this difference was of
borderline significance (p = 0.047).
Risk assessment outcomes: refer or manage
in primary care
Of the 1127 participants, 168 needed discussion with second-
ary care (uncertain risk), of which 64 (38%) were recommend-
ed referral (Fig. 1). Twenty-eight of the uncertain risk cases
were identified by the research team beyond that of the deci-
sion support software, of which 12 were recommended refer-
ral after discussion with secondary care. The final pathway for
all participants was the following: refer to secondary care for
128 participants and manage in primary care for 999
participants.
Box 1 (continued)
• State-Trait Anxiety Index (continuous)
• Positive and Negative Affect Schedule (continuous)
• Short Form–Six Dimensions (categorical)
• General health (categorical)
• Perceived risk of breast cancer (categorical)
• Medical Interview Satisfaction Scale (continuous)
Health behaviours
• Breast self-examination advice from the GP (GP records, yes/no)
• Breast self-examination, frequency (patient self-reported)
• Breast related GP consultation (GP records, yes/no)
• National Health Service health check last 5 years (GP records, yes/no)
• Combined oral contraception prescribed (GP records, yes/no)
• Progesterone only oral contraception prescribed (GP records, yes/no)
• Hormonal replacement therapy prescribed (GP records, yes/no)
• Ever had mammogram (patient self-reported, yes/no)
• Last mammogram (≤ 3 years, > 3 years, patient self-reported)
• Mammogram/ultrasound breast last 12 months (GP records, yes/no)
FDR first-degree relative, GP general practitioner, SDR second-degree
relative, vs versus
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Univariate analysis: factors associated
with recommendation for referral
From the univariate analysis of all factors listed in Box 1, six
variables were significant and included in the multivariable
model: five family history variables (breast cancer diagnosed
aged < 40, bilateral breast cancer, prostate cancer, first-degree
relatives (FDR) with ovarian cancer, paternal family history of
breast cancer) and one health behaviour variable (last
mammogram, Supplementary material 1, 2). The variable
‘breast cancer aged < 40’ had the strongest association with
recommendation for referral (OR 26.44, 95% CI 12.44 to
56.19). A small number of participants (n = 16) with family
history of non-FDR breast cancer aged < 40 did not meet the
NICE referral criteria; they were given the ‘Uncertain’ cate-
gory and after discussion with the specialists, referral was not
indicated for 10 participants.
Multivariable regression models
In the multivariable analysis including all 1127 participants,
the family history variable with the strongest association of
recommendation for referral was breast cancer in younger
women (aged < 40, AOR 22.12, 95% CI 9.36 to 52.30),
followed by bilateral breast cancer, relevant cancers (prostate
cancer, FDR with ovarian cancer) and breast cancer in the
paternal lineage (Table 2).
Participants whose lastmammogramwasmore than 3 years
ago or who did not report their last mammogram were less
likely to be recommended a secondary care referral (AOR
0.27, 95% CI 0.08 to 0.91; AOR 0.32, 95% CI 0.16 to 0.63
respectively). Of these 680 participants who did not have/
report a mammogram in the last 3 years, only 9% were not
compliant, the rest were not in the national breast cancer
screening age group of 50–70.
Combining these significant factors with age and IMD
quintiles a priori produced a predictive model with high dis-
criminatory accuracy (AUC 0.86, Supplementary material 3).
When this multivariable model was applied to the subgroup of
168 women with uncertain risk, the discrimination was re-
duced by 15% (AUC 0.71, Supplementary material 4).
Further, the only variable that remained significant was family
history of breast cancer in the paternal lineage (Table 3).
Discussion
Main findings and comparison with existing literature
This study confirmed the importance of certain family history
components when assessing familial breast cancer risk in pri-
mary care, namely breast cancer diagnosed age < 40, in both
breasts, or in the paternal lineage and related cancers such as
ovarian cancer in FDR and prostate cancer. These family his-
tory components held the greatest weight in deciding whether
referral was recommended by a decision support software
based on clinical guidelines. There was less clarity on the
predictors of referral for women with uncertain risk. As a
decision support software based on clinical guidelines was
used to decide whether referral was indicated or not, it was
not surprising that psychological factors did not influence re-
ferral recommendations.
These family history components are known risk factors
for breast cancer. A Lancet study which combined 52 epide-
miological studies found that the excess lifetime incidence of
breast cancer for women with one relative affected before age
40 compared with over age 60 is 3.8% (Collaborative Group















School level 169 (15)
Vocational education 106 (9)
College level 210 (19)
Higher education 269 (24)
Other 264 (23)
No formal qualification/still studying 101 (9)
Not reported 8 (1)
Occupation, ONS classification
Managers, directors, senior official 71 (6)
Professional occupations 218 (19)
Associate professional and technical occupations 127 (11)
Administrative and secretarial occupations 171 (15)
Skilled trades occupations 19 (2)
Personal service occupations 113 (10)
Sales and customer service occupations 50 (4)
Process, plant and machine operatives 9 (1)
Elementary occupations 52 (5)
Student/housewife/unemployed 152 (13)
Not reported 145 (13)
IMD (quintiles)




Least deprived 5 277 (25)
Not reported 62 (6)
IMD Index of Multiple Deprivation, IQR interquartile range, ONS Office for
National Statistics
NB non-white ethnicity included Black, Indian subcontinent, Mediterranean,
European Jewish, Brazilian, Philippine and mixed ethnicities
J Community Genet
on Hormonal Factors in Breast Cancer 2001). Bilateral breast
cancer and ovarian and prostate cancers are thought to be
associated with pathogenic variants in the BRCA1 and
BRCA2 genes (Petrucelli et al. 1998).
Family history of prostate cancer, which was identified as a
significant factor, is currently not included in clinical guide-
lines (NICE 2013). This is significant as a pathogenic variant
in the BRCA2 mutation gene in particular which is linked to
familial breast cancer also increases the risk of prostate cancer
(Cancer Research UK 2018a, b). The Women’s Health
Initiative observational study of over 70,000 women showed
that prostate cancer in a FDR increased a woman’s risk of
developing breast cancer (adjusted hazard ratio 1.14); this
increases to 78% when there is a family history of breast and
prostate cancers (Beebe-Dimmer et al. 2015).
Strengths and limitations
To our knowledge, this is the first study to evaluate factors
associated with referral recommendations for women under-
going familial breast cancer risk assessment in primary care,
as defined by clinical guidelines. The strength of this study
lies in the large sample size of 1127 participants who engaged
with the full familial breast cancer assessment. However, the
uptake rate in the original study was low, leading to responder
bias where women with a family history of breast cancer may
be more motivated to participate. Nevertheless, this model
would be applicable to a real-world setting where uptake
may be low when women were systematically invited for a
familial breast cancer risk assessment.
Comparisons of demographics were made between partic-
ipants and non-participants. The research team received
anonymised data from all potentially eligible women, but it
was not possible to identify from these women who were
excluded from being eligible in study participation by the
general practitioners due to privacy and data protection laws.
The availability of multiple data sources on the same per-
son enabled the exploration of a range of family history, psy-
chological, behavioural, sociodemographic and clinical fac-
tors. In-depth analysis of the family history was made possible
by the quality of the data collected using a structured, validat-
ed family history tool (Qureshi et al. 2005). The psychological
measures were also assessed using validated tools such as the
Lerman Breast Cancer Worry and State-Trait Anxiety Index
(Lerman et al. 1991; Spielberger et al. 1983).
We were not able to account for socioeconomic variation at
the general practice level as the small number of practices (n =
4) did not allow for a cluster effect analysis. Nevertheless,
socioeconomic variation at participant level was measured
using the IMD. The study population was predominantly
white and above average on the socioeconomic gradient.
The mammography uptake in this cohort suggests a re-
sponders bias, where women who are more concerned of their
familial breast cancer risk are more likely to participate in the
study. This, together with the lack of ethnic and socioeconom-
ic variation, limits the generalisation of findings to other pop-
ulation groups.
To strengthen the multivariable model, we used the 1127
cohort before applying it to the smaller uncertain risk group,
as the latter was too small to develop a multivariable model.
As a general rule of thumb, logistic regression for prognostic
modelling requires approximately 10 outcome events per pre-
dictor (Peduzzi et al. 1996). Similarly, the response rates in
certain categories were too small and had to be combined or
excluded from the analysis. For instance, Jewish ancestry, a
known risk factor for familial breast cancer, was not used as a
covariate because there were only four participants.
Future research recommendations
Several breast cancer risk prediction models such as the Gail
model and the Tyrer-Cuzick model included other breast cancer
Participants
1127
Manage in primary care
895 (79%)
Uncertain risk: discuss with 
secondary care
168 (15%)
Refer to secondary care
64 (6%)
Uncertain: Manage in 
primary care
104 (62%)
Uncertain: Refer to 
secondary care
64 (38%)
Final: Manage in primary 
care
999 (89%)





Fig. 1 Recommended clinical
pathway for 1127 participants
after familial breast cancer risk
assessment and discussion with
secondary care, uncertain risk
group highlighted in grey
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risk factors, for instance, weight and age of menarche (Amir
et al. 2003). These were not available for our analysis as the
original study focused on familial risk. These risk factors are
likely to be important predictors of the need for specialist as-
sessment for breast cancer risk and should be considered in
future research. To illustrate this, the PROCAS study compared
the number of breast cancers detected using NICE guidelines
versus the Tyrer-Cuzick model for familial breast cancer risk
assessment in women attending routine mammographic screen-
ing; the Tyrer-Cuzick model classified more women at risk
Table 2 Multivariable model predicting recommendation of secondary care referral for 1127 participants undergoing familial breast cancer risk
assessment in primary care, p < 0.0001
Variables Adjusted OR 95% CI p value
Age 0.97 0.93 to 1.01 0.11
IMD (quintiles)
Most deprived, 1 Reference
2 0.56 0.22 to 1.40 0.21
3 0.67 0.31 to 1.47 0.32
4 0.59 0.27 to 1.31 0.19
Least deprived, 5 0.84 0.39 to 1.82 0.66
Not available 0.82 0.29 to 2.31 0.71
Last mammogram
≤ 3 years Reference
> 3 years 0.27 0.08 to 0.91 0.04
Not reported 0.32 0.16 to 0.63 0.001
Family history of breast cancer aged < 40 22.12 9.36 to 52.30 < 0.001
Family history of bilateral breast cancer 12.36 5.31 to 28.80 < 0.001
Family history of prostate cancer 7.45 3.98 to 13.95 < 0.001
FDR with ovarian cancer 5.56 2.43 to 12.69 < 0.001
Paternal family history of breast cancer 3.79 2.22 to 6.47 < 0.001
CI confidence interval, FDR first-degree relative, IMD Index of Multiple Deprivation, OR odds ratio
Table 3 Multivariable model predicting recommendation of secondary care referral for 168 uncertain risk participants undergoing familial breast
cancer risk assessment in primary care, p = 0.01
Variables Adjusted OR 95% CI p value
Age 0.96 0.90 to 1.02 0.16
IMD (quintiles)
Most deprived, 1 Reference
2 0.64 0.16 to 2.53 0.53
3 1.15 0.37 to 3.57 0.81
4 0.76 0.23 to 2.58 0.67
Least deprived, 5 1.98 0.63 to 6.24 0.24
Not available 0.47 0.08 to 2.80 0.41
Last mammogram
≤ 3 years Reference
> 3 years 0.34 0.05 to 2.18 0.26
Not reported 0.47 0.16 to 1.37 0.17
Paternal family history of breast cancer 5.08 2.06 to 12.54 < 0.001
Family history of breast cancer aged < 40 0.61 0.17 to 2.17 0.45
Family history of bilateral breast cancer 0.58 0.18 to 1.85 0.35
Family history of prostate cancer 1.84 0.75 to 4.51 0.18
FDR with ovarian cancer 0.79 0.30 to 2.05 0.63
CI confidence interval, FDR first-degree relative, IMD Index of Multiple Deprivation, OR odds ratio
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(8.8% versus 3.7%) and detected more with breast cancer (8
versus 5 of 37 cases detected) (Evans et al. 2014).
The exploratory nature of this study may result in type 1
error: confirmation of the finding in a different dataset would
be desirable. The multivariable model also needs to be tested
on longer term outcomes, such as the outcomes after second-
ary care assessment or cancer incidence. The uncertain risk
group needs more investigation through other cohort studies
or qualitative methods involving clinicians to explore what
determines referral recommendations.
Conclusion and clinical implications
Clinical guideline recommends taking a comprehensive fam-
ily history when assessing familial breast cancer risk (NICE
2013). This can be challenging for primary care clinicians
who have limited consultation time. This study confirmed
the salient family history components that primary care clini-
cians need to pay particular attention to when identifying pa-
tients who need secondary care referral. Prostate cancer family
history needs to be considered when assessing a woman’s
familial breast cancer risk, in addition to the well-known risk
factors of breast and ovarian cancer family history.
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